Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

This article provides a thorough overview of the pathophysiology and current treatment options for myasthenia gravis, an autoimmune and antibody-mediated neuromuscular disease.

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) -- as well as three neonatal fragment ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile.

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment ...

26 Antozzi, C et al., Nipocalimab in Generalized Myasthenia Gravis: Results from a Double-Blind, Placebo-Controlled, Randomized Phase 3 Study. Abstract at 2024 European Academy of Neurology Congress.

Johnson & Johnson (NYSE: JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ (nipocalimab-aahu) versus ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis ...

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis ...